<DOC>
	<DOCNO>NCT00097981</DOCNO>
	<brief_summary>The purpose study determine Thalidomide + Dexamethasone DOXIL ( doxorubicin HCl liposome injection ) + Thalidomide + Dexamethasone effective treat newly diagnose patient multiple myeloma . The number patient whose multiple myeloma disappear period time ( complete Response ) study make determination treatment effective .</brief_summary>
	<brief_title>A Study Thalidomide Plus Dexamethasone ( Thal-Dex ) Versus DOXIL plusThalidomide Plus Dexamethasone ( DOXIL -Thal-Dex ) Patients With Newly Diagnosed Multiple Myeloma</brief_title>
	<detailed_description>This multi-center , open-label ( people know identity intervention ) , randomize ( study medication assign chance ) study compare safety effectiveness Thalidomide + Dexamethasone versus DOXIL ( doxorubicin HCl liposome injection ) + Thalidomide + Dexamethasone patient newly diagnose multiple myeloma . Treatments administer 28-day cycle . Patients receive 4 12 treatment cycle , depend response multiple myeloma treatment ( measure accord European Group Blood Marrow Transplant Response Criteria ) . Patients additional test include Multiple Gated Acquisition ( MUGA ) scan echocardiograms ass patient potential cardiotoxicity could relate treatment DOXIL ( doxorubicin HCl liposome injection ) . Maximum duration study participation participant 48 week .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Previously untreated , histologically confirm multiple myeloma ( per International Myeloma Working Group [ IMWG ] criterion Eastern Cooperative Oncology Group ( ECOG ) status 02 Adequate absolute neutrophil count ( ANC ) , platelet count hemoglobin Adequate serum calcium Enrollment System Thalidomide Education Prescribing Safety Program ( S.T.E.P.S . ) No treatment dexamethasone multiple myeloma No peripheral neuropathy Grade 2 high No Left Ventricular Ejection Fraction ( LVEF ) less 45 percentage No history lifethreatening thromboembolic event kind ( ie , myocardial infarction , pulmonary embolism , stroke others ) , within 1 year enrollment study No deep vein thrombosis ( DVT ) within 1 year enrollment No current anticoagulation DVT</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Multiple myeloma</keyword>
	<keyword>Newly diagnose multiple myeloma</keyword>
	<keyword>Thalidomide</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>DOXIL</keyword>
	<keyword>Pegylated liposomal hydrochloride doxorubicin injection</keyword>
</DOC>